Skip to main content
Top
Published in: International Urology and Nephrology 3/2007

01-09-2007 | Original Paper

Correlation between the total volume, transitional zone volume of the prostate, transitional prostate zone index and lower urinary tract symptoms (LUTS)

Authors: Mario Franciosi, Walter José Koff, Ernani Luis Rhoden

Published in: International Urology and Nephrology | Issue 3/2007

Login to get access

Abstract

Objectives

Currently available studies show controversial data between the symptoms of the lower urinary tract and the volume of the prostate gland. The objective of the present study is to evaluate the relationship between the score of the lower urinary tract symptoms assessed according to the International Prostate Symptoms Score (IPSS) and the total (TV) and transitional (TZV) zone volume of the prostate and transitional prostate zone index (TZI).

Materials and methods

From 223 men with a mean age of 59.3 years (varying from 50 to 75), the scores of lower urinary tract symptoms, measured by the IPSS and TV and TZV, determined by transrectal ultrasonographies, were obtained. Furthermore, the TZI was determined in all cases by the TZV to TV rate of the prostate. The relationship between TV, TZV, and TZI and the data obtained using the symptoms score was statistically determined.

Results

The TV of the prostate were 25.5 ± 10.3, 25.0 ± 9.3, and 28.9 ± 13.5 g in individuals with mild, moderate, and severe symptoms, respectively (P = 0.15). Similarly, there was no significant difference when the TZV (7.6 ± 6.3, 7.6 ± 5.8, and 9.6 ± 6.8 g, respectively; P = 0.22) and the TZI (0.26 ± 0.1, 0.27 ± 0.1, and 0.30 ± 0.1, respectively; P = 0.33) were compared in the groups of men with mild, moderate, and severe symptoms of urinary difficulty. However, the quality of life (QoL) scores presented progressively worse values (1.7 ± 1.3, 3.1 ± 1.4, and 4.4 ± 1.2) as the severity of the lower urinary tract symptoms became worse (P < 0.001). The Pearson correlation coefficient between the TV (r = 0.15; P = 0.02), TZV (r = 0.16; P = 0.02), and the TZI (r = 0.14; P = 0.03) with the prostate symptom scores showed low values although they were positive and statistically significant. The highest correlation was observed when the QoL related to urinary symptoms and symptom scores (r = 0.61; P < 0.001) was analyzed.

Conclusions

A low correlation was found between the score lower urinary tract symptoms assessed by IPSS and the different volumes of the prostate gland (TV, TZV) and prostate TZI, and, on the other hand, an inverse correlation between the intensity of urinary symptoms and QoL, supporting the idea of multifactorial aspects related to the genesis of urinary symptoms in men.
Literature
1.
go back to reference Shapiro E, Lepor H (1995) Pathophysiology of clinical benign prostatic hyperplasia. Urol Clin North Am 22(2):285–290PubMed Shapiro E, Lepor H (1995) Pathophysiology of clinical benign prostatic hyperplasia. Urol Clin North Am 22(2):285–290PubMed
2.
go back to reference Issacs JT, Coffey DS (1989) Etiology and disease process of benign prostatic hyperplasia. Prostate 2:33–50CrossRef Issacs JT, Coffey DS (1989) Etiology and disease process of benign prostatic hyperplasia. Prostate 2:33–50CrossRef
3.
go back to reference Guess HA, Arrighi HM, Metter EJ, Fozard JL (1990) Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia. Prostate 17(3):241–246PubMedCrossRef Guess HA, Arrighi HM, Metter EJ, Fozard JL (1990) Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia. Prostate 17(3):241–246PubMedCrossRef
4.
go back to reference Kirby RS (2000) The natural history of benign prostatic hyperplasia: what have we learned in the last decade? Urology 56(5 suppl 1):3–6PubMedCrossRef Kirby RS (2000) The natural history of benign prostatic hyperplasia: what have we learned in the last decade? Urology 56(5 suppl 1):3–6PubMedCrossRef
5.
go back to reference O’Leary MP (2000) LUTS, ED, QOL: alphabet soup or real concerns to aging men? Urology 56(5A):7–11PubMedCrossRef O’Leary MP (2000) LUTS, ED, QOL: alphabet soup or real concerns to aging men? Urology 56(5A):7–11PubMedCrossRef
6.
go back to reference Girmam CJ, Jacobsen SJ, Guess HA, Oesterling JE, Chute CG, Panser LA, Lieber MM (1995) Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. J Urol 153:1510–1515CrossRef Girmam CJ, Jacobsen SJ, Guess HA, Oesterling JE, Chute CG, Panser LA, Lieber MM (1995) Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. J Urol 153:1510–1515CrossRef
7.
go back to reference Osterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, Lieber MM (1993) Serum prostate specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 270(7):860–864CrossRef Osterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, Lieber MM (1993) Serum prostate specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 270(7):860–864CrossRef
8.
go back to reference Bosch JL, Kranse HR, Van Mastrigt R, Schröder FH (1995) Reasons for the weak correlation between prostate volume and urethral resistence parameters in patients with prostatism. J Urol 153(3 pt 1):689–693PubMed Bosch JL, Kranse HR, Van Mastrigt R, Schröder FH (1995) Reasons for the weak correlation between prostate volume and urethral resistence parameters in patients with prostatism. J Urol 153(3 pt 1):689–693PubMed
9.
go back to reference Barry MJ, Cockett AT, Holtgrewe HL, McConnell JD, Sihelnik SA, Winfield HN (1993) Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol 150(2 Pt 1): 351–358PubMed Barry MJ, Cockett AT, Holtgrewe HL, McConnell JD, Sihelnik SA, Winfield HN (1993) Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol 150(2 Pt 1): 351–358PubMed
10.
go back to reference McNeal JE (1988) The prostate gland: morphology and pathobiology. Monogr Urol 9:36–41 McNeal JE (1988) The prostate gland: morphology and pathobiology. Monogr Urol 9:36–41
11.
go back to reference Barry MJ, Fowler FJ, O′Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett ATK (1992) Measurement Committee of American Urological Association: The American Urological Association symptom index for benign prostate hyperplasia. J Urol 148(5):1549–1557PubMed Barry MJ, Fowler FJ, O′Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett ATK (1992) Measurement Committee of American Urological Association: The American Urological Association symptom index for benign prostate hyperplasia. J Urol 148(5):1549–1557PubMed
12.
go back to reference International Consensus Committee (1993) Recommendations of the International Consensus Committee. In: Cockett ATK, Khoury S, Aso Y et al. (eds) Proceedings of the 2nd International Consultation on Benign Prostate Hyperplasia (BPH). Jersey, Channel Islands, Scientific Communication International, p. 556–564 International Consensus Committee (1993) Recommendations of the International Consensus Committee. In: Cockett ATK, Khoury S, Aso Y et al. (eds) Proceedings of the 2nd International Consultation on Benign Prostate Hyperplasia (BPH). Jersey, Channel Islands, Scientific Communication International, p. 556–564
13.
go back to reference Yoshimura K, Arai Y, Ichioka K, Terada N, Matsuta Y, Okubo K (2002) Symptom-specific quality of life in patients with benign prostatic hyperplasia. Int J Urol 9:485–490PubMedCrossRef Yoshimura K, Arai Y, Ichioka K, Terada N, Matsuta Y, Okubo K (2002) Symptom-specific quality of life in patients with benign prostatic hyperplasia. Int J Urol 9:485–490PubMedCrossRef
14.
go back to reference Desgrandchamps F, Droupy S, Irani J, Saussine C, Comenducci A (2006) Effects of dutasteride on the symptoms of benign prostatic hyperplasia, and patient quality of life and discomfort, in clinical practice. Br J Urol Int 98:83–88 Desgrandchamps F, Droupy S, Irani J, Saussine C, Comenducci A (2006) Effects of dutasteride on the symptoms of benign prostatic hyperplasia, and patient quality of life and discomfort, in clinical practice. Br J Urol Int 98:83–88
15.
go back to reference Gacci M, Bartoletti R, Figlioli S, Sarti FE, Eisner B, Bodd V, Rizzo M (2003) Urinary symptoms, quality of life and sexual function in patients with benign prostatic hypertrophy before and after prostatectomy: a prospective study. Br J Urol Int 91:196–200 Gacci M, Bartoletti R, Figlioli S, Sarti FE, Eisner B, Bodd V, Rizzo M (2003) Urinary symptoms, quality of life and sexual function in patients with benign prostatic hypertrophy before and after prostatectomy: a prospective study. Br J Urol Int 91:196–200
16.
go back to reference Sukov RJ, Scardino PT, Sample WF, Winter J, Confer DJ (1977) Computed tomography and transabdominal ultrasound in the evaluation of the prostate. J Comput Assist Tomogr 1(3):281–289PubMedCrossRef Sukov RJ, Scardino PT, Sample WF, Winter J, Confer DJ (1977) Computed tomography and transabdominal ultrasound in the evaluation of the prostate. J Comput Assist Tomogr 1(3):281–289PubMedCrossRef
17.
go back to reference Roehrborn CG, Bartsch G, Kirby R, Andriole G, Boyle P, De La Rosette J, Perrin P, et al (2001) Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: a comparative international overview. Urology 58:642–650PubMedCrossRef Roehrborn CG, Bartsch G, Kirby R, Andriole G, Boyle P, De La Rosette J, Perrin P, et al (2001) Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: a comparative international overview. Urology 58:642–650PubMedCrossRef
18.
go back to reference Chute CG, Guess HA, Panser LA, Johnson CL, Jacobsen SJ, Oesterling JE, Lieber MM (1993) The non-relationship of urinary symptoms prostate volume and uroflow in a population based sample of men. J Urol 149:356 Chute CG, Guess HA, Panser LA, Johnson CL, Jacobsen SJ, Oesterling JE, Lieber MM (1993) The non-relationship of urinary symptoms prostate volume and uroflow in a population based sample of men. J Urol 149:356
19.
go back to reference Overland GB, Vatten L, Rhodes T, De Muro C, Jaconbsen G, Vada K, Angelsen A, et al (2001) Lower urinary tract symptom prostate volume and uroflow in Norwegian community men. Eur Urol 39(1):36–41PubMedCrossRef Overland GB, Vatten L, Rhodes T, De Muro C, Jaconbsen G, Vada K, Angelsen A, et al (2001) Lower urinary tract symptom prostate volume and uroflow in Norwegian community men. Eur Urol 39(1):36–41PubMedCrossRef
20.
go back to reference Greene DR, Egawa S, Hellerstein DK, Scardino PT (1990) Sonographic measurements of transition zone of prostate in men with and without benign prostatic hyperplasia. Urology 36(4):293–299PubMedCrossRef Greene DR, Egawa S, Hellerstein DK, Scardino PT (1990) Sonographic measurements of transition zone of prostate in men with and without benign prostatic hyperplasia. Urology 36(4):293–299PubMedCrossRef
21.
go back to reference Kaplan AS, Te AE, Pressler LB, Olsson CA (1995) Transition zone index as a method of assessing benign prostatic hyperplasia: correlation with symptoms, urine flow and detrusor pressure. J Urol 154(5):1764–1769PubMedCrossRef Kaplan AS, Te AE, Pressler LB, Olsson CA (1995) Transition zone index as a method of assessing benign prostatic hyperplasia: correlation with symptoms, urine flow and detrusor pressure. J Urol 154(5):1764–1769PubMedCrossRef
22.
go back to reference Kaplan AS, Reis RB, Staimen VB, Te AE (1998) Is the ratio of transition zone to total prostate volume in their Caucasian Africa-American men than in their Caucasian or hispanic counterparts? Br J Urol 82(6):804–807PubMed Kaplan AS, Reis RB, Staimen VB, Te AE (1998) Is the ratio of transition zone to total prostate volume in their Caucasian Africa-American men than in their Caucasian or hispanic counterparts? Br J Urol 82(6):804–807PubMed
23.
go back to reference Caine M, Pfau A, Perlberg S (1976) The use of alpha-adrenergic blockers in benign prostatic obstruction. Br J Urol 48(4):255–263PubMedCrossRef Caine M, Pfau A, Perlberg S (1976) The use of alpha-adrenergic blockers in benign prostatic obstruction. Br J Urol 48(4):255–263PubMedCrossRef
24.
go back to reference Hutch JA, Rambo ON Jr (1970) A study of the anatomy of the prostate, prostatic urethra and the urinary sphincter system. J Urol 104(3):443–452PubMed Hutch JA, Rambo ON Jr (1970) A study of the anatomy of the prostate, prostatic urethra and the urinary sphincter system. J Urol 104(3):443–452PubMed
25.
go back to reference Grayhack JT, McVary KT, Kozlowski JM (2002) Benign prostatic hyperplasia. In: Gllenwater J, Grayhack JT, Howards S (eds) Adult and pediatric urology. St Louis, Mosby, 2, pp. 1401–1470 Grayhack JT, McVary KT, Kozlowski JM (2002) Benign prostatic hyperplasia. In: Gllenwater J, Grayhack JT, Howards S (eds) Adult and pediatric urology. St Louis, Mosby, 2, pp. 1401–1470
26.
go back to reference Gotoh M, Kamihira O, Kinukawa T, Ono Y, Ohshima S, Origasa H (2005) Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. Br J Urol Inter 96(4):581 Gotoh M, Kamihira O, Kinukawa T, Ono Y, Ohshima S, Origasa H (2005) Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. Br J Urol Inter 96(4):581
27.
go back to reference Haltbakk J, Hanestad BR, Hunskaar S (2005) How important are men lower urinary tract symptoms (LUTS) and their impact on the quality of life (QoL). Qual Life Res Sep 14(7):1733–1741CrossRef Haltbakk J, Hanestad BR, Hunskaar S (2005) How important are men lower urinary tract symptoms (LUTS) and their impact on the quality of life (QoL). Qual Life Res Sep 14(7):1733–1741CrossRef
Metadata
Title
Correlation between the total volume, transitional zone volume of the prostate, transitional prostate zone index and lower urinary tract symptoms (LUTS)
Authors
Mario Franciosi
Walter José Koff
Ernani Luis Rhoden
Publication date
01-09-2007
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 3/2007
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-006-9148-8

Other articles of this Issue 3/2007

International Urology and Nephrology 3/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine